drugset / Trial / NCT02164500
JAK-inhibition in Recurrent Classical Hodgkin Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The Purpose of this trial is: * to determine the overall response rate (ORR, complete response \[CR\] + partial response \[PR\]) in patients with relapsed or refractory HL * to determine the safety profile of ruxolitinib in patients with relapsed or refractory HL
Timeline
- Start
- 2015-10
- Primary completion
- 2019-05-17
- Completion
- 2019-05-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruxolitinib | Small molecule | — | — |